1033723-45-3

Upstream product

• 608119-82-0 1-(4-(benzyloxy)-2-methylphenyl)ethanone 
• 100-39-0 benzyl bromide 
• 898538-71-1 4-(benzyloxy)-5-bromo-2-methylbenzaldehyde 
• 957774-01-5 4-benzyloxy-5-bromo-2-methylbenzoic acid 
• 875-59-2 4'-hydroxy-2'methylacetophenone 
• 1033723-27-1 [4-(benzyloxy)-5-bromo-2-methylphenyl](4-methoxyphenyl)methanol 

Downstream Products

• 1033723-37-3 (1S)-1,5-anhydro-1-[5-(4-methoxybenzyl)-4-methyl-2-hydroxyphenyl]-1-thio-D-glucitol 
• 1033723-57-7 (1S)-1,5-anhydro-2,3,4,6-tetra-O-benzyl-1-[2-(benzyloxy)-5-(4-methoxybenzyl)-4-methylphenyl]-1-thio-D-glucitol 

Relevant academic research and scientific papers

Discovery of a potent, low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor (TP0438836) for the treatment of type 2 diabetes

The design and synthesis of a novel class of low-absorbable SGLT1 inhibitors are described. To achieve low absorption in the new series, we performed an optimization study based on a strategy to increase TPSA. Fortunately, the optimization of an aglycon m

1-PHENYL 1-THIO-D-GLUCITOL DERIVATIVE

A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like: or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.